Literature DB >> 16613999

Comprehensive detection of disorders of purine and pyrimidine metabolism by HPLC with electrospray ionization tandem mass spectrometry.

Susen Hartmann1, Jürgen G Okun, Christiane Schmidt, Claus-Dieter Langhans, Sven F Garbade, Peter Burgard, Dorothea Haas, Jörn Oliver Sass, William L Nyhan, Georg F Hoffmann.   

Abstract

BACKGROUND: Clinical presentation and disease severity in disorders of purine and pyrimidine metabolism vary considerably. We present a method that allows comprehensive, sensitive, and specific diagnosis of the entire spectrum of abnormalities in purine and pyrimidine metabolism in 1 analytical run.
METHODS: We used reversed-phase HPLC electrospray ionization tandem mass spectrometry to investigate 24 metabolites of purine and pyrimidine metabolism in urine samples from healthy persons and from patients with confirmed diagnoses of inherited metabolic disorders. Urine samples were filtered and diluted to a creatinine concentration of 0.5 mmol/L. Stable-isotope-labeled internal standards were used for quantification. The metabolites were analyzed by multiple-reaction monitoring in positive and negative ionization modes.
RESULTS: Total time of analysis was 20 min. Recovery (n = 8) of a compound after addition of a known concentration was 85%-133%. The mean intraday variation (n = 10) was 12%. The interday variation (n = 7) was < or =17%. Age-related reference intervals were established for each compound. Analysis of patient urine samples revealed major differences in tandem mass spectrometry profiles compared with those of control samples. Twelve deficiencies were reliably detected: hypoxanthine guanine phosphoribosyl transferase, xanthine dehydrogenase, purine nucleoside phosphorylase, adenylosuccinate lyase, uridine monophosphate synthase, adenosine deaminase, adenine phosphoribosyl transferase, molybdenum cofactor, thymidine phosphorylase, dihydropyrimidine dehydrogenase, dihydropyrimidinase, and beta-ureidopropionase.
CONCLUSION: This method enables reliable detection of 13 defects in purine and pyrimidine metabolism in a single analytical run.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613999     DOI: 10.1373/clinchem.2005.058842

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

1.  Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry.

Authors:  James J Pitt
Journal:  Clin Biochem Rev       Date:  2009-02

2.  Metabolic disorders of purine metabolism affecting the nervous system.

Authors:  H A Jinnah; Richard L Sabina; Georges Van Den Berghe
Journal:  Handb Clin Neurol       Date:  2013

3.  Quantitative UPLC-MS/MS assay of urinary 2,8-dihydroxyadenine for diagnosis and management of adenine phosphoribosyltransferase deficiency.

Authors:  Margret Thorsteinsdottir; Unnur A Thorsteinsdottir; Finnur F Eiriksson; Hrafnhildur L Runolfsdottir; Inger M Sch Agustsdottir; Steinunn Oddsdottir; Baldur B Sigurdsson; Hordur K Hardarson; Nilesh R Kamble; Snorri Th Sigurdsson; Vidar O Edvardsson; Runolfur Palsson
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-09-14       Impact factor: 3.205

4.  High levels of blood glutamic acid and ornithine in children with intellectual disability.

Authors:  Muhammad Wasim; Haq Nawaz Khan; Hina Ayesha; Abdul Tawab; Fazal E Habib; Muhammad Rafique Asi; Mazhar Iqbal; Fazli Rabbi Awan
Journal:  Int J Dev Disabil       Date:  2020-12-21

5.  Urinary 2,8-dihydroxyadenine excretion in patients with adenine phosphoribosyltransferase deficiency, carriers and healthy control subjects.

Authors:  Hrafnhildur L Runolfsdottir; Runolfur Palsson; Unnur A Thorsteinsdottir; Olafur S Indridason; Inger M Sch Agustsdottir; G Steinunn Oddsdottir; Margret Thorsteinsdottir; Vidar O Edvardsson
Journal:  Mol Genet Metab       Date:  2019-05-28       Impact factor: 4.797

6.  Inborn errors of pyrimidine metabolism: clinical update and therapy.

Authors:  Shanti Balasubramaniam; John A Duley; John Christodoulou
Journal:  J Inherit Metab Dis       Date:  2014-07-17       Impact factor: 4.982

7.  High-glucose toxicity is mediated by AICAR-transformylase/IMP cyclohydrolase and mitigated by AMP-activated protein kinase in Caenorhabditis elegans.

Authors:  Christin Riedinger; Michael Mendler; Andrea Schlotterer; Thomas Fleming; Jürgen Okun; Hans-Peter Hammes; Stephan Herzig; Peter P Nawroth
Journal:  J Biol Chem       Date:  2018-02-02       Impact factor: 5.157

Review 8.  Adenylosuccinate lyase deficiency.

Authors:  Agnieszka Jurecka; Marie Zikanova; Stanislav Kmoch; Anna Tylki-Szymańska
Journal:  J Inherit Metab Dis       Date:  2014-08-12       Impact factor: 4.982

9.  Extended diagnosis of purine and pyrimidine disorders from urine: LC MS/MS assay development and clinical validation.

Authors:  Péter Monostori; Glynis Klinke; Jana Hauke; Sylvia Richter; Jörgen Bierau; Sven F Garbade; Georg F Hoffmann; Claus-Dieter Langhans; Dorothea Haas; Jürgen G Okun
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

10.  Clinical and genetic analysis of 7 Chinese patients with β-ureidopropionase deficiency.

Authors:  Yulian Fang; Chunquan Cai; Chao Wang; Bei Sun; Xinjie Zhang; Wenxuan Fan; Wenchao Hu; Yingtao Meng; Shuxiang Lin; Chunhua Zhang; Yuqin Zhang; Jianbo Shu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.